A review of patient perspectives on generics substitution: what are the challenges for optimal drug use
Journal Title: Generics and Biosimilars Initiative Journal - Year 2012, Vol 1, Issue 1
Abstract
Introduction: With a few exceptions, generic drug use has been promoted in western countries by allowing pharmacists to substitute drugs defined as therapeutically equivalent generics. The aim of this literature review is to summarise the research on the patients’ perspectives of generics substitution in the western world between 2000 and 2011 with special emphasis on the challenges these attitudes present for optimal drug use. Methods: A literature search was undertaken in MEDLINE (PubMed), Embase (Ovid), and SciVerse Scopus with the aim of identifying all the peer reviewed, original research articles concerning patient perspectives on generics substitution in western countries published between 1 January 2000 and 1 March 2011. Results: The 20 studies included in this review indicate that close to one-third of all patients were uneasy about having their drug(s) substituted generically. Between 8–34% of patients reported poorer effects and/or new side effects after a change—except for antiepileptic drug users from which the number of reports was even higher. Poor awareness of generics substitution caused confusion and reduced the patients’ willingness and ability to take their medication as prescribed. Patients’ acceptance of generics substitution was influenced by age, educational levels, perceptions about disease, generic drug information, and who informed them about the change. The studies consistently suggested a continuing need for information directed at patients and an increased involvement of physicians. Conclusion: This literature review suggests that although generics substitution is well accepted by the majority of patients, about one-third of the patients report negative experiences which may lead to poor adherence and medication errors.
Authors and Affiliations
Helle Håkonsen, Else-Lydia Toverud
Keywords
Related Articles
- EP ID EP355198
- DOI 10.5639/gabij.2012.0101.008
- Views 128
- Downloads 0
Maximizing quality in the manufacture of biologicals
Biological product quality is susceptible to unexpected manufacturing issues, and the resulting variation may impact the safety or efficacy of these medicines and increase risks to patients. These risks can be managed mo...
Efficient production of recombinant parathyroid hormone (rPTH) fragment 1-34 in the methylotrophic yeast Hansenula polymorpha
Background: Osteoporosis is a bone disease of the elderly that leads to increased risk of fracture. Currently, it affects more than 200 million adults worldwide, placing an enormous economic burden on healthcare provider...
Pharmacovigilance of biosimilars: challenges and possible solutions
Post-marketing surveillance is essential to detect, assess and prevent adverse reactions of chemically synthesized small molecule drugs as well as biologicals, as the full safety profile can only be known after they have...
The ethics of biosimilars
Comment on the Letters to the Editor by Dr Carlo Petrini: A bioethicist’s view of the use of biosimilars, published in GaBI Journal, 2012, issue 3-4.
A bioethicist’s view of the use of biosimilars
In recognition of the many ethically sensitive issues raised by the production and use of biosimilar medicinal products, the author imagines having to answer the non-multiple choice question ‘From the ethical point of vi...